19. May 2021

Our publication Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent: A multicenter Prospective Study was accepted by the Journal of Vascular Interventional Radiology.

The EASYX I clinical trial results reveals a clear statement the PVA generation of Liquid Embolic Agents (LEA)are safe and efficient and do have advantages against all other LEAs

The use of cyanoacrylates, used for embolization for a long period of time, has decreased in the last decades, they are currently still used not anymore for their embolic properties but due to their low-price advantage: in most countries, cyanoacrylates are much cheaper than Onyx, Squid, PHIL or EASYX.

Well-known drawbacks of the EVOH (Ethylene vinyl alcohol) based generation LEAs (liquid embolic agencies) in particular Onyx and Squid are

  • the frequent and heavy imaging artifacts which occur predominantly in CT imaging due to their Tantalum content
  • the degree of toxicity and the inflammatory effects on the embolized vessels leads to a painful therapy which inevitably requires the use of perioperative administration of anti-inflammatory drugs, such as corticosteroids and adequate sedation is needed
  • the fact that they appear black due to the admixed tantalum powder, can lead to macroscopically visible black colorization of superficially embolized blood vessels

Available clinical studies on the following HEMA (Hydroxyethyl methacrylate) based LEAs per example PHIL reported less artifacts compared to Onyx and Squid this thanks to the absence of tantalum.
Unfortunately, here the drawbacks are:

  • the radiopacity in the HEMO based LEAs are created by a nonstable ester linkage to graft iodine with the negative effect that the radiopacity disappears after some time. So, on the one hand, the visibility improves perioperatively, but on the other hand, the visibility disappears postoperatively due to the degradable radiopacity, which is a major problem in redo cases or postoperative bleeding.
  • Vasotoxic and inflammatory effects on the embolized vessels are still a topic but less than compared to EVOH based products (ONYXS and SQUID) – the toxic effects are mainly caused by the admixed high concentration of DMSO what leads to painful administration of the embolic liquid which requires perioperative administration of analgesic medication.

The use the Polyvinyl alcohol (PVA) copolymer LEA based generation “EASYX” with a High biostability, non-degradable radiopacity, lower volume and concentration of the used DMSO and no metal substances (Tantalum) gives:

  • particularly no CT/MRI-artifacts anymore – clear visibility
  • significant improvements on the detection of peri or postprocedural hemorrhages compared to the HEMA based product (P.Ex. Phil)
  • the toxic effects are reduced to a minimum mainly because of the less injected and lower concentration DMSO used as with Phil and a statistical reduced toxicity as the EVOH based products. This benefits the patient as no analgesic or pain reduction medication is needed anymore
  • It has been demonstrated that EASYX ® precipitates with a 1.3 times greater surface volume per mL of liquid embolic injection than as the HEMO based and even more up to1.5 times in comparison EVOH based products
  • an optimal homogenous plug formation within max 3 minutes injection results in a reduced fluoroscopy time equal to less radiation time for the patient.
  • a further advantage of EASYX is that it does not need any kind of preparation before its use. In an emergency, EASYX can be immediately used for the embolization. And the syringes can be refilled as much as is necessary for the treatment
Our publication Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent: A multicenter Prospective Study was accepted by the Journal of Vascular Interventional Radiology.

31. May 2022

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

Treatment of the Femoro-Popliteal district with the innovative Exist NiTi Stent (QMEDICS) type Flex & Pull: the HORIZON clinical trial. Marone E.M.1, Rinaldi …

28. February 2022

Qmedics is proud to announce the first Enrolment in the “HORIZON” trial for the Treatment of PAD

The Horizon study will provide information on the long-term outcomes of the innovative EXIST NiTi self- expandable stent with its two types of …

30. November 2021

Qmedics has obtained the Good Manufacturing Practices (GMP) certificate for its quality control, cleanroom facility and medical device manufacturing activities at its Swiss-based facility in Zürich- Flurlingen in November 2021

I am very pleased that Qmedics AG has been able to achieve the GMP certification. A GMP certification in general is granted to …

28. February 2021

First EasyX Case report in Nicosia General Hospital, Cyprus

A 64-year Old patient presented to the nephrostomy department of Nicosia General Hospital with chronic allograft nephropathy and elevation of the inflammatory markers …

31. January 2021

A milestone reached EASYX I trial closed successfully

COVID-19 has created challenges in every aspects of healthcare. Due to the current pandemic, the medical device industry has been under tremendous pressure …

31. August 2020

Qmedics Peripheral stent system family

After two and a half years of hard work finally we present the new peripheral stent family.It was a difficult path: The R&D …

30. July 2020

PTA Qmedics product family Manatee-Naga-Nova is launched

The rise in the prevalence of cardiovascular diseases and peripheral vascular diseases, adaptation to a sedentary lifestyle, better healthcare facilities are key factors …

30. September 2019

Qmedics achieved to close with success the first investigator meeting

“Horizon” Clinical investigation of the Qmedics Exist NiTi Stent portfolio with the Flex & Pull type in adults with Peripheral Artery Disease (PAD). …

31. July 2019

NEW PRODUCT added to our Portfolio

The EASYX™ Liquid Embolic is a new injectable, precipitating polymeric agent for the obliteration of vascular spaces through direct puncture or catheter access …

31. October 2018

New Organization for Qmedics

In 2016 the Board of Directors decided to sell the sister company of Qmedics, who was at the same time the biggest customer …

28. September 2018

Qmedics team at Cirse

Our travel did start with a strike of the taxi drivers, a delay in our shipment of workshop material- but as a team …

31. July 2018

First workshop: Endovascular treatments of PAD

With the organization of workshops the professionals get to understand the two stent types “ Pull & Flex”. The first workshop “Endovascular treatments …

30. March 2018

Exist & Manatee launched in “Der Schweiz”

As a Swiss company we are very pleased that our improved QM1 “Exist” a product entirely developed at our facility “made in Switzerland” …

3. January 2018

LINC congress: Presentation of our innovative product portfolio

Already a whole year qmedics R&D engineers are working on this concept and with success.The Finite element analysis (FEA), the bench testing and …

22. December 2017

Qmedics receives DIN EN ISO 13485:2016 Certificate

Qmedics is proud to announce its DIN EN ISO 13485:2016 certification.The company is now in the right to develop, manufacture and market medical …

Copyright © 2023 Qmedics AG. All rights reserved.

Watch the video